# US 2022/0016037 A1 · Colonic drug delivery formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016037 A1
- Document ID: US20220016037A1
- Status: Published application
- Kind: A1
- Application number: 17/309,558
- Filed: 2019-12-05
- Published: 2022-01-20
- Earliest claimed: 2018-12-07
- Assignees: Tillotts Pharma AG
- Applicants: Tillotts Pharma AG
- Inventors: Felipe Varum; Roberto Carlos Bravo González
- Web page: https://patentgrep.com/patent/US20220016037A1

## CPC

- A61K 9/286: {Polysaccharides, e.g. gums; Cyclodextrin}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/606: having amino groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A delayed release drug formulation contains a core containing a drug and a delayed release coating for intestinal release, where release of the drug in the colon is not hindered by the absence of an alkaline middle layer between the core and the outer layer. The delayed release coating contains an outer coating, and optionally, an isolation layer. The outer coating contains a mixture of an enzymatically degradable polysaccharide which is degradable by colonic enzymes selected from the group of starch, amylose, amylopectin, chitosan, chondroitin sulfate, cyclodextrin, dextran, ptallulan, carrageenan, scleroglucan, curdulan, and levan and a film-forming enteric polymer having a pH threshold at about pH 6 or above. The enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of more than 60:40.

## Claims

### Claim 1

A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising:
a core comprising a drug and optionally, an isolation layer; and
an outer coating for the core, the outer coating comprising a mixture of an enzymatically degradable polysaccharide which is susceptible to attack by colonic enzymes selected from the group consisting of starch, amylose, amylopectin, chitosan, chondroitin sulfate, cyclodextrin, dextran, pullulan, carrageenan, scleroglucan, chitin, curdulan, and. levan; and a film-forming enteric polymer having a pH threshold at about pH 6 or above,
wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of more than 60:40; and
wherein the outer coating is in direct contact with the surface of the uncoated core or, if present, the isolation layer.

### Claim 2 (depends on 1)

The delayed release drug formulation as claimed in claim 1, wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of about 65:35 to about 90:10.

### Claim 3 (depends on 1)

A The delayed release drug formulation as claimed in claim 1, wherein the enteric polymer is present in the outer coating in an amount from about 4 mg/cm2 to about 6 mg/cm2, based on the dry weight of the enteric polymer.

### Claim 4 (depends on 1)

The delayed release drug formulation as claimed in claim 1, wherein the core comprises an isolation layer.

### Claim 5 (depends on 4)

The delayed release drug formulation as claimed in claim 4, wherein the isolation layer comprises a film-forming non-ionic polymer.

### Claim 6 (depends on 5)

The delayed release drug formulation as claimed in claim 5, wherein the non-ionic polymer is a non-ionic cellulose-based polymer.

### Claim 7 (depends on 1)

A method of producing the delayed release drug formulation for oral administration to deliver a drug to the colon as claimed in claim 1, said method comprising:
forming the core comprising the drug and, optionally, the isolation layer, and
coating the core directly with an outer coating preparation comprising the enzymatically degradable polysaccharide which is susceptible to attack by colonic enzymes selected from the group consisting of starch, amylose, amylopectin, chitosan, chondroitin sulfate, cyclodextrin, dextran, carrageenan, scleroglucan, chitin, curdulan, and levan; and the film-forming enteric polymer having a pH threshold at about pH 6 or above in a solvent, to form an outer coated core,
wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer layer in a ratio of more than 60:40.

### Claim 8 (depends on 7)

The method as claimed in claim 7, comprising initially coating the core with an isolation layer coating preparation comprising a film-forming non-ionic polymer in a solvent, to form an isolated core for coating with the outer coating preparation.

### Claim 9 (depends on 8)

The method as claimed in claim 8, wherein the non-ionic polymer is a non-ionic cellulose-based polymer.

### Claim 10 (depends on 7)

The method as claimed in claim 7, wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating preparation in a ratio of about 65:35 to about 90;10.

### Claim 11 (depends on 7)

The method as claimed in claim 7, wherein the core is coated with the outer coating preparation until the enteric polymer is coated on to the core in an amount from about 4 m2/cm2 to about 6 mg/cm2, based on the dry weight of the enteric polymer.

### Claim 12 (depends on 2)

The delayed release drug formulation as claimed in claim 2, wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of about 75:25.

### Claim 13 (depends on 3)

The delayed release drug formulation as claimed in claim 3, wherein the enteric polymer is present in the outer coating in an amount of about 5 mg/cm', based on the dry weight of the enteric polymer.

### Claim 14 (depends on 10)

The method as claimed in claim 10, wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating preparation in a ratio of about 75:25.

### Claim 15 (depends on 11)

The method as claimed in claim 11, wherein the core is coated with the outer coating preparation until the enteric polymer is coated on to the core in an amount of about 5 mg/cm2, based on the dry weight of the enteric polymer.
